Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
Albania, a small country in Southeast Europe, has a developing Pharmaceuticals market that is constantly growing and evolving.
Customer preferences: Albanians are known to be very health-conscious and value the importance of maintaining good health. As a result, the demand for pharmaceutical products has been increasing in recent years. Customers in Albania tend to prefer generic drugs due to their lower cost compared to branded drugs. Additionally, there is a growing demand for over-the-counter (OTC) drugs, which can be purchased without a prescription.
Trends in the market: The Albanian Pharmaceuticals market has been experiencing growth in recent years, with a significant increase in the number of companies operating in the market. This growth is largely due to the increasing demand for pharmaceutical products in Albania. The market is also seeing a trend towards the production of generic drugs, which are cheaper alternatives to branded drugs. Additionally, there has been a shift towards the production of biopharmaceuticals, which are used to treat a range of diseases such as cancer, diabetes, and autoimmune disorders.
Local special circumstances: One of the challenges facing the Albanian Pharmaceuticals market is the lack of investment in research and development. This has resulted in a limited number of locally produced pharmaceutical products, with the majority of products being imported from other countries. Additionally, there is a lack of regulation in the market, which has led to the sale of counterfeit drugs in some areas.
Underlying macroeconomic factors: Albania's economy has been growing steadily in recent years, with a focus on developing the country's infrastructure and attracting foreign investment. The government has implemented policies to encourage foreign investment in the pharmaceuticals sector, which has led to an increase in the number of companies operating in the market. Additionally, the country's population is increasing, which is driving demand for pharmaceutical products. However, there are still challenges facing the market, such as a lack of investment in research and development and the need for better regulation.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)